HPV positivity in HIV+ women: 1 in 5 screened at Gujarat's GCRI tests positive
Synopsis
Key Takeaways
Nearly one in five women living with HIV who underwent cervical cancer screening at the Gujarat Cancer Research Institute (GCRI) in Ahmedabad have tested positive for the human papillomavirus (HPV), according to data from an ongoing integrated screening initiative. The programme also detected one case of early-stage cervical cancer, underscoring the critical need for targeted oncological screening among immunocompromised women.
Key Findings from the Screening Data
Since the initiative was launched in March 2025, GCRI has screened 1,542 HIV-positive women using HPV DNA testing at the Antiretroviral Therapy (ART) Centre at Ahmedabad's Civil Hospital. Of those screened, 319 women — or 20.69% — returned a positive HPV result, while 1,223 tested negative.
This positivity rate is markedly higher than those recorded among Gujarat's general population — 4.82% in urban areas and 5.22% in rural areas — highlighting the disproportionate vulnerability of women living with HIV to persistent high-risk HPV infections, which significantly elevate the risk of cervical cancer development.
Colposcopy Results and Cancer Detection
Following initial HPV screening, 150 women were referred for colposcopy — a more detailed examination of the cervix. The investigations identified 94 cases of cervical intraepithelial neoplasia (CIN), a condition involving precancerous abnormal cell changes in cervical tissue.
The breakdown included 63 cases of CIN 1, 30 cases of CIN 2, and one case of CIN 3. One additional case of early-stage cervical cancer was detected, enabling timely medical intervention that may prove lifesaving. Notably, CIN 2 and CIN 3 represent more advanced precancerous changes that require close monitoring and treatment to prevent progression.
Why This Integration Matters
The programme was designed to embed cervical cancer detection into routine HIV care — a model that health experts have long advocated for, given that women living with HIV face a significantly higher burden of persistent high-risk HPV infections. Without targeted screening, precancerous lesions in this population frequently go undetected until they reach advanced, harder-to-treat stages.
This comes amid broader national efforts to reduce India's cervical cancer burden. India accounts for a substantial share of global cervical cancer deaths, and the disease disproportionately affects women in lower-income groups who have limited access to regular gynaecological care.
Award Recognition and Expansion Plans
The initiative has been recognised with the FICCI Healthcare Excellence Award 2026 in the 'Excellence in Patient Care and Service Delivery' category, acknowledging its model of integrating cancer prevention and early diagnosis into routine HIV treatment services.
GCRI, which is jointly managed by the Gujarat state government and the Gujarat Cancer Society, plans to extend the integrated screening model to other ART centres across the state, subject to practical feasibility and resource availability. The programme is being implemented in alignment with the state's broader preventive healthcare agenda and efforts to improve early diagnosis access.
As the model matures, its replication across other states with significant HIV-positive populations could meaningfully shift outcomes for a group that has historically fallen through the gaps between infectious disease care and cancer prevention services.